Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
Epistemonikos ID: 2e7fcc273746dd6c2d8023d24ae6879bfeb12c87
First added on: Feb 19, 2024